oxybutynin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
spasmolytics with a papaverine-like action 2028 5633-20-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • oxybutynin hydrochloride
  • oxybutynin
  • oxybutynin chloride
  • oxytrol
  • ditropan
  • kentera
  • oxybutynin HCl
Oxybutynin acts as a competitive antagonist of acetylcholine at post-ganglionic muscarinic receptors, resulting in relaxation of bladder smooth muscle. Oxybutynin is a racemic (50:50) mixture of R- and S-isomers. Antimuscarinic activity resides predominantly in the R-isomer. The R-isomer of oxybutynin shows greater selectivity for the M1 and M3 muscarinic subtypes (predominant in bladder detrusor muscle and parotid gland) compared to the M2 subtype (predominant in cardiac tissue).
  • Molecular weight: 357.49
  • Formula: C22H31NO3
  • CLOGP: 4.69
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 1
  • TPSA: 49.77
  • ALOGS: -4.55
  • ROTB: 10
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
15 mg O
3.90 mg TD

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.80 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.93 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 6 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.85 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 5.10 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.00 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 7.20 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 3.230 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 0.701 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 55.847 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 82.794 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 5.610 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 4.410 % High 1
herg hERG pIC50 5.203 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 174.985 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 296.483 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 3.700 % High 1
kinase-safety-class ACVR2B,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,MAPK7,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PRKDC,TEK,TGFBR1 22
kinase-selectivity-class AXL,EIF2AK3,GRK2,PDK4 4
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 2.415 High 1
mh-clint Mouse hepatocyte intrinsic clearance 216.272 High 1
mppb Mouse plasma protein binding (% unbound) 5.900 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 6.855 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 0 High 1
pppb Pig plasma protein binding (% unbound) 12.030 % High 1
rh-clint Rat hepatocyte intrinsic clearance 300.608 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 34.060 % High 1
rppb Rat plasma protein binding (% unbound) 6.730 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 314.775 uM High 1

Approvals:

DateAgencyCompanyOrphan
July 16, 1975 FDA
March 27, 2023 PMDA Hisamitsu Pharmaceutical Co., Inc.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Urinary tract infection 349.43 10.92 586 45474 305046 90277341
Multiple sclerosis relapse 278.30 10.92 223 45837 52082 90530305
Fall 261.47 10.92 680 45380 481130 90101257
Vaginal flatulence 192.12 10.92 104 45956 12534 90569853
Proctitis 184.31 10.92 108 45952 15151 90567236
Female genital tract fistula 176.07 10.92 111 45949 17757 90564630
Radiculopathy 172.50 10.92 111 45949 18394 90563993
Multiple sclerosis 161.62 10.92 125 45935 27715 90554672
Systemic lupus erythematosus 161.25 10.92 5 46055 361891 90220496
Vaginal discharge 160.16 10.92 108 45952 19356 90563031
Chronic sinusitis 151.70 10.92 113 45947 23689 90558698
Urinary incontinence 150.26 10.92 136 45924 37430 90544957
Hand deformity 132.34 10.92 4 46056 296358 90286029
Synovitis 129.67 10.92 10 46050 329742 90252645
Glossodynia 128.70 10.92 9 46051 321770 90260617
Oral candidiasis 118.13 10.92 116 45944 35339 90547048
Contraindicated product administered 117.10 10.92 13 46047 320126 90262261
Pericarditis 109.65 10.92 7 46053 270144 90312243
Application site erythema 108.51 10.92 53 46007 5155 90577232
Maternal exposure during pregnancy 100.83 10.92 29 46031 360034 90222353
Paraesthesia oral 98.86 10.92 100 45960 31559 90550828
Duodenal ulcer perforation 95.25 10.92 4 46056 221284 90361103
Joint swelling 94.16 10.92 71 45989 503229 90079158
Constipation 92.54 10.92 333 45727 280062 90302325
Folliculitis 90.34 10.92 3 46057 204350 90378037
Hepatic enzyme increased 88.97 10.92 36 46024 360700 90221687
Macular degeneration 88.87 10.92 103 45957 37867 90544520
Balance disorder 80.08 10.92 162 45898 96918 90485469
Colitis ulcerative 78.72 10.92 123 45937 60143 90522244
Wound 78.43 10.92 28 46032 302952 90279435
Haematochezia 78.11 10.92 134 45926 70779 90511608
Muscle injury 76.67 10.92 3 46057 176651 90405736
Procedural pain 75.58 10.92 89 45971 33271 90549116
Urine analysis abnormal 71.19 10.92 40 46020 5181 90577206
Exposure during pregnancy 70.90 10.92 17 46043 238393 90343994
Liver injury 70.46 10.92 4 46056 170563 90411824
Colitis 69.08 10.92 126 45934 69816 90512571
Abdominal discomfort 65.62 10.92 88 45972 477240 90105147
Arthropathy 65.50 10.92 54 46006 366188 90216199
Impaired healing 65.27 10.92 19 46041 234180 90348207
Frequent bowel movements 64.57 10.92 109 45951 56826 90525561
Gait disturbance 63.87 10.92 282 45778 260214 90322173
Rectal haemorrhage 63.44 10.92 134 45926 82610 90499777
Treatment failure 63.32 10.92 38 46022 303890 90278497
Micturition urgency 62.07 10.92 49 46011 11184 90571203
Drug intolerance 61.02 10.92 83 45977 447508 90134879
Blister 57.29 10.92 29 46031 254969 90327418
Application site pruritus 56.45 10.92 32 46028 4215 90578172
Product dose omission issue 53.06 10.92 290 45770 291397 90290990
Stomatitis 52.27 10.92 38 46022 274660 90307727
Psoriatic arthropathy 49.76 10.92 27 46033 228308 90354079
Erythema 49.39 10.92 239 45821 229007 90353380
Swelling 49.17 10.92 86 45974 418972 90163415
Product adhesion issue 48.30 10.92 31 46029 5111 90577276
Pollakiuria 48.25 10.92 71 45989 32934 90549453
Hypertonic bladder 47.88 10.92 29 46031 4319 90578068
General physical health deterioration 45.27 10.92 69 45991 355046 90227341
Mental status changes 44.76 10.92 81 45979 44598 90537789
Therapeutic product effect decreased 44.75 10.92 45 46015 277526 90304861
Laboratory test abnormal 44.66 10.92 78 45982 41776 90540611
Weight decreased 44.01 10.92 337 45723 379573 90202814
Joint range of motion decreased 43.75 10.92 8 46052 135635 90446752
Lower respiratory tract infection 43.51 10.92 38 46022 250621 90331766
Irritable bowel syndrome 43.10 10.92 26 46034 207422 90374965
Type 2 diabetes mellitus 42.89 10.92 25 46035 203219 90379168
Secondary progressive multiple sclerosis 41.93 10.92 19 46041 1560 90580827
Hallucination, visual 41.71 10.92 55 46005 23037 90559350
Dry mouth 39.71 10.92 192 45868 183867 90398520
Swollen joint count increased 39.42 10.92 5 46055 111201 90471186
Injury 39.26 10.92 26 46034 197323 90385064
Bladder disorder 39.19 10.92 37 46023 10735 90571652
Neurogenic bladder 39.14 10.92 24 46036 3654 90578733
Hallucination 38.57 10.92 96 45964 65863 90516524
Discomfort 38.24 10.92 50 46010 274285 90308102
White blood cells urine positive 37.32 10.92 29 46031 6469 90575918
Nephrolithiasis 35.90 10.92 78 45982 49007 90533380
Cystitis 35.79 10.92 94 45966 66624 90515763
Application site rash 35.18 10.92 20 46040 2649 90579738
Product use issue 34.91 10.92 72 45988 329847 90252540
Wheezing 34.63 10.92 42 46018 238038 90344349
Bladder spasm 34.50 10.92 18 46042 2012 90580375
Bacterial test 34.48 10.92 15 46045 1118 90581269
Urine leukocyte esterase positive 33.86 10.92 21 46039 3261 90579126
Rheumatoid arthritis 33.62 10.92 85 45975 362529 90219858
Urinary sediment present 33.34 10.92 18 46042 2156 90580231
Culture urine positive 33.33 10.92 22 46038 3803 90578584
Urine abnormality 32.88 10.92 29 46031 7708 90574679
Wound infection 32.79 10.92 7 46053 106395 90475992
Lip dry 32.45 10.92 6 46054 100949 90481438
Hypercholesterolaemia 32.43 10.92 6 46054 100886 90481501
Breast cancer stage III 31.95 10.92 3 46057 84444 90497943
Red blood cells urine positive 31.68 10.92 20 46040 3205 90579182
Gastrointestinal disorder 31.63 10.92 51 46009 256636 90325751
Escherichia urinary tract infection 31.52 10.92 37 46023 13778 90568609
Fibromyalgia 30.41 10.92 36 46024 206233 90376154
Monocyte percentage increased 30.39 10.92 14 46046 1194 90581193
Band neutrophil percentage increased 30.33 10.92 9 46051 218 90582169
Lymphocyte percentage decreased 29.74 10.92 19 46041 3108 90579279
Head injury 29.29 10.92 55 46005 31133 90551254
Dysuria 29.25 10.92 63 45997 39338 90543049
Incontinence 29.04 10.92 35 46025 13400 90568987
Ill-defined disorder 28.63 10.92 31 46029 184860 90397527
Liver disorder 28.43 10.92 13 46047 121256 90461131
Speech disorder 28.41 10.92 68 45992 45517 90536870
Lymphocyte count decreased 28.30 10.92 58 46002 34992 90547395
Somnolence 27.93 10.92 192 45868 208892 90373495
Urinary retention 27.62 10.92 60 46000 37684 90544703
Crystal urine present 27.60 10.92 14 46046 1476 90580911
Myelocyte percentage increased 27.23 10.92 8 46052 187 90582200
Grip strength decreased 26.73 10.92 7 46053 92569 90489818
Feeling abnormal 26.27 10.92 160 45900 167075 90415312
Urine oxalate increased 25.52 10.92 8 46052 234 90582153
Thrombocytopenia 25.21 10.92 42 46018 208683 90373704
Band neutrophil count increased 25.12 10.92 9 46051 400 90581987
Blood cholesterol increased 24.99 10.92 42 46018 207970 90374417
Hypersensitivity 24.71 10.92 133 45927 454544 90127843
Lung disorder 24.49 10.92 24 46036 149859 90432528
Malaise 24.13 10.92 425 45635 585561 89996826
Chronic obstructive pulmonary disease 23.71 10.92 87 45973 73742 90508645
Retinal depigmentation 23.60 10.92 8 46052 301 90582086
Inflammation 23.42 10.92 34 46026 178558 90403829
C-reactive protein increased 23.33 10.92 35 46025 181354 90401033
Dysmetropsia 23.31 10.92 6 46054 84 90582303
Vertigo 23.04 10.92 83 45977 69728 90512659
Peripheral venous disease 23.02 10.92 7 46053 83914 90498473
Pulmonary fibrosis 22.99 10.92 13 46047 107490 90474897
Bursitis 22.78 10.92 20 46040 131634 90450753
Malignant neoplasm progression 22.75 10.92 13 46047 106857 90475530
Lymphopenia 22.30 10.92 41 46019 22840 90559547
Alopecia 22.11 10.92 154 45906 494917 90087470
Headache 22.08 10.92 584 45476 862162 89720225
Off label use 21.85 10.92 412 45648 1101840 89480547
Application site vesicles 21.71 10.92 12 46048 1505 90580882
Nasopharyngitis 21.61 10.92 120 45940 406984 90175403
Intentional product use issue 21.55 10.92 49 46011 216843 90365544
Resting tremor 21.49 10.92 10 46050 873 90581514
Myelocyte count increased 21.28 10.92 8 46052 408 90581979
Decubitus ulcer 21.12 10.92 28 46032 11785 90570602
Muscular weakness 20.99 10.92 178 45882 206488 90375899
Oedema 20.93 10.92 44 46016 200251 90382136
Neutrophil percentage increased 20.81 10.92 15 46045 2988 90579399
Faecaloma 20.65 10.92 26 46034 10405 90571982
Prescribed overdose 20.60 10.92 12 46048 97613 90484774
Talipes 20.57 10.92 12 46048 1668 90580719
Therapy cessation 20.29 10.92 52 46008 36309 90546078
Musculoskeletal pain 20.18 10.92 35 46025 171216 90411171
Dizziness 20.01 10.92 415 45645 588869 89993518
Autoimmune disorder 19.99 10.92 7 46053 76737 90505650
Febrile neutropenia 19.93 10.92 31 46029 158318 90424069
Congenital uterine anomaly 19.89 10.92 6 46054 154 90582233
Psychotic symptom 19.71 10.92 13 46047 2243 90580144
Condition aggravated 19.51 10.92 201 45859 595344 89987043
Sleep disorder 19.46 10.92 45 46015 197985 90384402
Arthralgia 19.34 10.92 279 45781 778243 89804144
Completed suicide 19.24 10.92 133 45927 144925 90437462
Specific gravity urine decreased 19.23 10.92 9 46051 796 90581591
Adjustment disorder with depressed mood 19.06 10.92 3 46057 56750 90525637
Application site irritation 18.86 10.92 12 46048 1949 90580438
Rash 18.85 10.92 288 45772 795812 89786575
Peripheral swelling 18.69 10.92 128 45932 412978 90169409
Night sweats 18.41 10.92 23 46037 128743 90453644
On and off phenomenon 18.30 10.92 13 46047 2530 90579857
Obesity 18.29 10.92 16 46044 105491 90476896
Sinusitis 18.28 10.92 101 45959 342987 90239400
Musculoskeletal stiffness 18.25 10.92 83 45977 296449 90285938
Asthenia 18.15 10.92 376 45684 533375 90049012
Food refusal 18.01 10.92 8 46052 627 90581760
Cerebral atrophy 17.92 10.92 18 46042 5628 90576759
Nocturia 17.87 10.92 24 46036 10231 90572156
Depression 17.77 10.92 232 45828 300369 90282018
Urinary tract infection pseudomonal 17.74 10.92 9 46051 949 90581438
Haematocrit decreased 17.61 10.92 54 46006 41778 90540609
Prescription drug used without a prescription 17.56 10.92 14 46046 3241 90579146
Urine odour abnormal 17.53 10.92 20 46040 7224 90575163
White blood cell count decreased 17.53 10.92 145 45915 166964 90415423
Mixed incontinence 17.52 10.92 5 46055 105 90582282
Impaired self-care 17.49 10.92 11 46049 1751 90580636
Cerebrovascular accident 17.42 10.92 115 45945 123418 90458969
Hallucinations, mixed 17.29 10.92 18 46042 5871 90576516
Anorectal malformation 17.23 10.92 6 46054 245 90582142
Vision blurred 16.98 10.92 105 45955 110188 90472199
Lagophthalmos 16.86 10.92 7 46053 465 90581922
Device programming error 16.83 10.92 6 46054 263 90582124
Anaemia 16.75 10.92 262 45798 352540 90229847
Neutrophil count increased 16.74 10.92 33 46027 19357 90563030
Dermatitis contact 16.71 10.92 27 46033 13568 90568819
Injection related reaction 16.58 10.92 9 46051 1090 90581297
Haemoglobin urine present 16.42 10.92 8 46052 774 90581613
Dementia 16.41 10.92 37 46023 23824 90558563
Urticaria 16.15 10.92 93 45967 312641 90269746
Tremor 16.12 10.92 133 45927 153040 90429347
Peroneal nerve palsy 15.86 10.92 17 46043 5731 90576656
Sciatica 15.69 10.92 17 46043 101365 90481022
Pregnancy 15.59 10.92 6 46054 62041 90520346
Central nervous system lesion 15.52 10.92 24 46036 11622 90570765
Exostosis 15.37 10.92 4 46056 53130 90529257
Drug-induced liver injury 15.29 10.92 14 46046 90304 90492083
Sepsis 15.26 10.92 149 45911 179665 90402722
Bladder pain 15.25 10.92 12 46048 2725 90579662
Anticholinergic syndrome 15.23 10.92 12 46048 2731 90579656
Back pain 15.22 10.92 236 45824 316939 90265448
Infusion related reaction 15.18 10.92 137 45923 416643 90165744
Hip fracture 15.15 10.92 44 46016 33033 90549354
Pneumonia influenzal 15.09 10.92 11 46049 2229 90580158
Body height decreased 15.06 10.92 24 46036 11925 90570462
Hyperacusis 14.97 10.92 12 46048 2799 90579588
Drug withdrawal syndrome neonatal 14.75 10.92 11 46049 2308 90580079
Trigeminal neuralgia 14.66 10.92 14 46046 4117 90578270
Thyroglobulin increased 14.55 10.92 4 46056 73 90582314
Hepatic cirrhosis 14.48 10.92 7 46053 63246 90519141
Kidney infection 14.39 10.92 37 46023 25879 90556508
Bladder operation 14.39 10.92 8 46052 1015 90581372
Nail disorder 14.37 10.92 6 46054 59061 90523326
Muscle spasticity 14.31 10.92 45 46015 35277 90547110
Repetitive strain injury 14.18 10.92 5 46055 212 90582175
Renal aplasia 14.15 10.92 6 46054 420 90581967
Skin irritation 14.05 10.92 25 46035 13578 90568809
Ileus paralytic 13.97 10.92 15 46045 5070 90577317
Syncope 13.85 10.92 115 45945 132548 90449839
Impaired gastric emptying 13.83 10.92 24 46036 12785 90569602
Lethargy 13.70 10.92 66 45994 63073 90519314
Coeliac disease 13.61 10.92 3 46057 44607 90537780
Neuralgia 13.57 10.92 41 46019 31459 90550928
Pyelonephritis 13.50 10.92 32 46028 21284 90561103
Open fracture 13.41 10.92 6 46054 478 90581909
Product closure removal difficult 13.41 10.92 3 46057 22 90582365
Dysarthria 13.33 10.92 59 46001 54423 90527964
Anal incontinence 13.27 10.92 27 46033 16203 90566184
Haemoglobin decreased 13.16 10.92 133 45927 161823 90420564
Incision site pruritus 13.07 10.92 3 46057 25 90582362
Urinary tract infection bacterial 12.98 10.92 16 46044 6269 90576118
Vitamin D deficiency 12.95 10.92 28 46032 17528 90564859
Injection site scar 12.86 10.92 8 46052 1249 90581138
Abdominal pain 12.86 10.92 277 45783 395444 90186943
Burning sensation 12.82 10.92 65 45995 63387 90519000
Product administered at inappropriate site 12.75 10.92 13 46047 4138 90578249
Magnetic resonance imaging abnormal 12.73 10.92 12 46048 3474 90578913
Dermatitis atopic 12.51 10.92 33 46027 23439 90558948
Urosepsis 12.51 10.92 31 46029 21201 90561186
Dry skin 12.42 10.92 82 45978 87991 90494396
Product residue present 12.39 10.92 13 46047 4278 90578109
Ankle fracture 12.28 10.92 30 46030 20340 90562047
Blood urine present 12.11 10.92 27 46033 17251 90565136
Urinary tract disorder 12.09 10.92 12 46048 3699 90578688
Hypertonia 12.08 10.92 14 46046 5141 90577246
Stress urinary incontinence 12.07 10.92 10 46050 2442 90579945
Seizure 11.76 10.92 124 45936 152505 90429882
Application site swelling 11.75 10.92 6 46054 641 90581746
Mental impairment 11.58 10.92 26 46034 16694 90565693
Klebsiella test positive 11.56 10.92 8 46052 1495 90580892
Hip arthroplasty 11.55 10.92 13 46047 76195 90506192
Citric acid urine increased 11.46 10.92 3 46057 45 90582342
Blepharospasm 11.44 10.92 7 46053 55438 90526949
Familial haemophagocytic lymphohistiocytosis 11.40 10.92 3 46057 46 90582341
Application site pain 11.37 10.92 13 46047 4707 90577680
Vulvovaginal mycotic infection 11.34 10.92 15 46045 6299 90576088
Chromaturia 11.29 10.92 28 46032 19159 90563228
Abnormal behaviour 11.25 10.92 31 46029 22597 90559790
Product use in unapproved indication 11.18 10.92 113 45947 336123 90246264
Mean cell haemoglobin decreased 10.96 10.92 14 46046 5681 90576706

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Urinary tract infection 172.38 13.18 195 15153 99089 42506898
Dry mouth 114.55 13.18 103 15245 39776 42566211
Fall 103.40 13.18 247 15101 234273 42371714
Urinary retention 81.90 13.18 88 15260 42126 42563861
Confusional state 80.85 13.18 183 15165 167414 42438573
Multiple sclerosis relapse 75.91 13.18 53 15295 14211 42591776
Muscle spasticity 63.14 13.18 36 15312 6786 42599201
Delirium 52.97 13.18 79 15269 52440 42553547
Completed suicide 46.04 13.18 105 15243 96360 42509627
Neurogenic bladder 41.68 13.18 19 15329 2241 42603746
Multiple sclerosis 39.88 13.18 28 15320 7570 42598417
Muscular dystrophy 37.46 13.18 9 15339 135 42605852
Constipation 36.66 13.18 135 15213 162156 42443831
Disorganised speech 32.78 13.18 14 15334 1414 42604573
Intestinal pseudo-obstruction 29.56 13.18 15 15333 2240 42603747
Bladder spasm 28.45 13.18 12 15336 1175 42604812
Hallucination 26.75 13.18 62 15286 57445 42548542
Syncope 26.14 13.18 87 15261 99319 42506668
Dizziness 23.59 13.18 162 15186 249092 42356895
Daydreaming 23.15 13.18 9 15339 714 42605273
Perthes disease 18.71 13.18 3 15345 3 42605984
Dysuria 17.26 13.18 36 15312 31060 42574927
Cystitis interstitial 16.93 13.18 5 15343 170 42605817
Urinary incontinence 16.89 13.18 29 15319 21639 42584348
Haemorrhage urinary tract 16.64 13.18 10 15338 2076 42603911
Agitation 16.64 13.18 56 15292 64258 42541729
Anticholinergic syndrome 16.37 13.18 9 15339 1580 42604407
Nephrolithiasis 16.35 13.18 39 15309 36791 42569196
Gait disturbance 16.13 13.18 74 15274 97926 42508061
Mental status changes 15.97 13.18 42 15306 42073 42563914
Fatigue 15.84 13.18 232 15116 435409 42170578
Bladder catheterisation 15.71 13.18 7 15341 783 42605204
Hypertonic bladder 15.42 13.18 10 15338 2371 42603616
Cystitis 15.37 13.18 20 15328 11678 42594309
Implant site erosion 15.12 13.18 4 15344 90 42605897
Micturition urgency 15.11 13.18 20 15328 11878 42594109
Cognitive disorder 14.97 13.18 36 15312 34136 42571851
Hallucination, visual 14.92 13.18 27 15321 20993 42584994
Pollakiuria 14.83 13.18 28 15320 22477 42583510
Haematuria 14.66 13.18 50 15298 57749 42548238
Balance disorder 14.62 13.18 44 15304 47601 42558386
Urosepsis 14.28 13.18 22 15326 14998 42590989
Vision blurred 14.10 13.18 47 15301 53652 42552335
Lumbar puncture abnormal 14.10 13.18 3 15345 25 42605962
Clonus 14.04 13.18 11 15337 3509 42602478
Escherichia urinary tract infection 13.97 13.18 12 15336 4351 42601636
Muscular weakness 13.70 13.18 63 15285 83435 42522552
Hydronephrosis 13.63 13.18 19 15329 11846 42594141
Injection site inflammation 13.35 13.18 7 15341 1119 42604868
Asthenia 13.30 13.18 157 15191 280636 42325351

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Urinary tract infection 449.79 10.90 641 49445 325641 110213572
Multiple sclerosis relapse 288.75 10.90 214 49872 50026 110489187
Fall 271.56 10.90 739 49347 602743 109936470
Vaginal flatulence 156.03 10.90 86 50000 12058 110527155
Chronic sinusitis 155.76 10.90 112 49974 24972 110514241
Female genital tract fistula 143.91 10.90 91 49995 16428 110522785
Proctitis 139.40 10.90 90 49996 16837 110522376
Macular degeneration 137.45 10.90 98 49988 21561 110517652
Vaginal discharge 137.19 10.90 91 49995 17817 110521396
Radiculopathy 135.56 10.90 93 49993 19243 110519970
Multiple sclerosis 124.65 10.90 99 49987 25599 110513614
Paraesthesia oral 107.17 10.90 102 49984 33569 110505644
Systemic lupus erythematosus 101.37 10.90 3 50083 254335 110284878
Urinary incontinence 98.92 10.90 116 49970 48471 110490742
Constipation 93.04 10.90 364 49722 357422 110181791
Synovitis 89.08 10.90 10 50076 274082 110265131
Urinary retention 85.69 10.90 130 49956 69553 110469660
Oral candidiasis 81.53 10.90 101 49985 44659 110494554
Dry mouth 78.91 10.90 234 49852 199714 110339499
Procedural pain 77.59 10.90 88 49998 35477 110503736
Urine analysis abnormal 72.89 10.90 43 50043 6854 110532359
Contraindicated product administered 71.49 10.90 13 50073 248254 110290959
Neurogenic bladder 70.89 10.90 38 50048 5041 110534172
Application site erythema 70.07 10.90 39 50047 5571 110533642
Treatment failure 67.12 10.90 21 50065 277213 110262000
Glossodynia 63.12 10.90 12 50074 221992 110317221
Duodenal ulcer perforation 61.65 10.90 5 50081 177695 110361518
Folliculitis 60.21 10.90 4 50082 167649 110371564
Joint swelling 58.11 10.90 69 50017 442776 110096437
Pericarditis 57.89 10.90 14 50072 219100 110320113
Hepatic enzyme increased 57.83 10.90 37 50049 320855 110218358
Maternal exposure during pregnancy 55.42 10.90 23 50063 254860 110284353
Completed suicide 54.57 10.90 236 49850 242145 110297068
Application site pruritus 52.17 10.90 29 50057 4131 110535082
Mental status changes 52.16 10.90 110 49976 76012 110463201
Drug intolerance 51.58 10.90 65 50021 406447 110132766
Gait disturbance 49.53 10.90 253 49833 277955 110261258
Balance disorder 49.41 10.90 140 49946 116420 110422793
Laboratory test abnormal 48.30 10.90 78 50008 44001 110495212
Micturition urgency 47.67 10.90 51 50035 19269 110519944
Hallucination, visual 47.43 10.90 73 50013 39532 110499681
Nephrolithiasis 46.90 10.90 97 49989 66115 110473098
C-reactive protein abnormal 46.85 10.90 3 50083 129692 110409521
Wound 46.56 10.90 24 50062 234413 110304800
Confusional state 45.90 10.90 366 49720 468314 110070899
Escherichia urinary tract infection 45.89 10.90 46 50040 16116 110523097
Impaired healing 45.67 10.90 16 50070 196701 110342512
General physical health deterioration 45.15 10.90 77 50009 425218 110113995
Bladder spasm 44.68 10.90 23 50063 2809 110536404
Hallucination 44.14 10.90 123 49963 101309 110437904
Exposure during pregnancy 43.63 10.90 11 50075 167413 110371800
Product dose omission issue 43.00 10.90 271 49815 321511 110217702
Muscle spasticity 42.73 10.90 66 50020 35849 110503364
Haematochezia 42.54 10.90 132 49954 115392 110423821
Colitis ulcerative 42.07 10.90 102 49984 77261 110461952
Arthropathy 40.77 10.90 42 50044 287480 110251733
Syncope 39.45 10.90 189 49897 202347 110336866
Colitis 38.68 10.90 118 49968 102205 110437008
White blood cells urine positive 38.67 10.90 30 50056 7494 110531719
Intestinal pseudo-obstruction 38.32 10.90 22 50064 3334 110535879
Psoriatic arthropathy 37.81 10.90 21 50065 196740 110342473
Dysuria 37.79 10.90 84 50002 60147 110479066
Frequent bowel movements 37.63 10.90 93 49993 71297 110467916
Cystitis 36.91 10.90 88 49998 65948 110473265
Culture urine positive 35.83 10.90 24 50062 4772 110534441
Liver disorder 35.82 10.90 10 50076 142233 110396980
Bacterial test 35.45 10.90 15 50071 1174 110538039
Blister 34.81 10.90 31 50055 227345 110311868
Hypertonic bladder 33.66 10.90 24 50062 5278 110533935
Urine leukocyte esterase positive 33.33 10.90 21 50065 3765 110535448
Urinary sediment present 32.74 10.90 18 50068 2510 110536703
Weight decreased 31.83 10.90 338 49748 467719 110071494
Delirium 31.54 10.90 133 49953 134892 110404321
Stomatitis 31.44 10.90 46 50040 270196 110269017
Incontinence 31.03 10.90 38 50048 16597 110522616
Irritable bowel syndrome 30.87 10.90 18 50068 164197 110375016
Muscular dystrophy 30.57 10.90 9 50077 239 110538974
Bladder disorder 30.34 10.90 31 50055 11106 110528107
Joint range of motion decreased 29.88 10.90 9 50077 121823 110417390
Urine abnormality 29.79 10.90 28 50058 9068 110530145
Lower respiratory tract infection 29.65 10.90 40 50046 243066 110296147
Interstitial lung disease 29.59 10.90 13 50073 139321 110399892
Pollakiuria 29.27 10.90 63 50023 44132 110495081
Myelosuppression 29.27 10.90 4 50082 94336 110444877
Swelling 29.24 10.90 73 50013 350968 110188245
Abdominal discomfort 29.00 10.90 87 49999 393771 110145442
Therapeutic product effect decreased 28.99 10.90 41 50045 244275 110294938
Bladder pain 28.37 10.90 17 50069 2788 110536425
Off label use 28.33 10.90 494 49592 1499691 109039522
Application site rash 27.81 10.90 16 50070 2434 110536779
Erythema 27.62 10.90 226 49860 291221 110247992
Gastrointestinal disorder 27.35 10.90 42 50044 241910 110297303
Lip dry 27.21 10.90 6 50080 100077 110439136
Rectal haemorrhage 27.19 10.90 117 49969 119716 110419497
Hallucinations, mixed 27.02 10.90 26 50060 8667 110530546
Urine oxalate increased 26.90 10.90 8 50078 220 110538993
Myelocyte percentage increased 26.60 10.90 8 50078 229 110538984
Thrombocytopenia 26.45 10.90 76 50010 348809 110190404
Wheezing 26.34 10.90 47 50039 255183 110284030
Band neutrophil percentage increased 26.25 10.90 9 50077 395 110538818
Dyspepsia 26.22 10.90 162 49924 190803 110348410
Type 2 diabetes mellitus 26.14 10.90 25 50061 177207 110362006
Speech disorder 26.13 10.90 74 50012 61495 110477718
Hypercholesterolaemia 25.62 10.90 5 50081 90832 110448381
Dementia 25.55 10.90 49 50037 31624 110507589
Crystal urine present 25.41 10.90 14 50072 1960 110537253
Breast cancer stage III 25.40 10.90 3 50083 79114 110460099
Red blood cells urine positive 25.19 10.90 20 50066 5165 110534048
Vision blurred 24.82 10.90 120 49966 128902 110410311
Lymphocyte percentage decreased 24.77 10.90 20 50066 5290 110533923
Lung disorder 24.73 10.90 27 50059 180020 110359193
C-reactive protein increased 24.46 10.90 38 50048 217881 110321332
Febrile neutropenia 24.01 10.90 69 50017 316698 110222515
Wound infection 23.88 10.90 7 50079 96458 110442755
Monocyte percentage increased 23.40 10.90 14 50072 2289 110536924
Retinal depigmentation 23.18 10.90 8 50078 358 110538855
Hepatic function abnormal 23.01 10.90 6 50080 89289 110449924
Urosepsis 22.98 10.90 46 50040 30629 110508584
Swollen joint count increased 22.78 10.90 5 50081 83656 110455557
Red blood cell sedimentation rate increased 22.74 10.90 4 50082 78298 110460915
Intentional product use issue 22.69 10.90 49 50037 247857 110291356
Secondary progressive multiple sclerosis 22.63 10.90 12 50074 1557 110537656
Specific gravity urine decreased 22.56 10.90 10 50076 876 110538337
Condition aggravated 22.29 10.90 219 49867 734617 109804596
Ill-defined disorder 22.12 10.90 23 50063 156830 110382383
Night sweats 22.07 10.90 17 50069 133966 110405247
Dizziness 22.06 10.90 441 49645 697752 109841461
Bursitis 22.02 10.90 16 50070 129902 110409311
Impaired self-care 22.02 10.90 14 50072 2550 110536663
Dysmetropsia 21.94 10.90 6 50080 121 110539092
Obesity 21.91 10.90 12 50074 113339 110425874
Muscular weakness 21.59 10.90 189 49897 248279 110290934
Head injury 21.58 10.90 55 50031 42962 110496251
Faecaloma 21.50 10.90 30 50056 14878 110524335
Clonus 21.49 10.90 23 50063 8693 110530520
Dysarthria 21.33 10.90 85 50001 84036 110455177
Band neutrophil count increased 21.25 10.90 9 50077 706 110538507
Somnolence 21.24 10.90 217 49869 297232 110241981
Urinary tract infection bacterial 21.15 10.90 22 50064 8045 110531168
Malaise 21.11 10.90 424 49662 671395 109867818
Disorganised speech 21.08 10.90 15 50071 3288 110535925
Headache 20.89 10.90 535 49551 881842 109657371
Injury 20.78 10.90 30 50056 177235 110361978
Product adhesion issue 19.99 10.90 14 50072 2992 110536221
Daydreaming 19.65 10.90 10 50076 1192 110538021
Decubitus ulcer 19.61 10.90 32 50054 18204 110521009
Grip strength decreased 19.52 10.90 6 50080 80168 110459045
Peripheral venous disease 19.25 10.90 7 50079 84110 110455103
Ascites 19.17 10.90 9 50077 92799 110446414
Device programming error 19.13 10.90 7 50079 372 110538841
Urinary tract infection pseudomonal 18.75 10.90 12 50074 2210 110537003
Kidney infection 18.71 10.90 38 50048 25561 110513652
Inflammation 18.69 10.90 37 50049 193201 110346012
Dermatitis contact 18.53 10.90 27 50059 13926 110525287
Therapy cessation 18.15 10.90 53 50033 44804 110494409
Hyperacusis 17.91 10.90 13 50073 2939 110536274
Body height decreased 17.90 10.90 23 50063 10540 110528673
Anticholinergic syndrome 17.63 10.90 15 50071 4265 110534948
Abnormal behaviour 17.63 10.90 48 50038 38991 110500222
Multiple organ dysfunction syndrome 17.46 10.90 26 50060 151684 110387529
Application site vesicles 17.18 10.90 10 50076 1554 110537659
Fibromyalgia 17.16 10.90 32 50054 170877 110368336
Feeling abnormal 17.03 10.90 140 49946 180571 110358642
Rheumatoid arthritis 16.86 10.90 74 50012 299539 110239674
Psychotic symptom 16.85 10.90 14 50072 3853 110535360
Neutropenia 16.85 10.90 100 49986 374520 110164693
Malignant neoplasm progression 16.39 10.90 34 50052 174533 110364680
Product use issue 16.35 10.90 79 50007 311616 110227597
Lymphocyte count decreased 16.28 10.90 60 50026 57183 110482030
Lagophthalmos 16.20 10.90 7 50079 577 110538636
Drug resistance 16.11 10.90 3 50083 56371 110482842
Myelocyte count increased 16.11 10.90 8 50078 906 110538307
Discomfort 16.10 10.90 47 50039 214660 110324553
Haemoglobin urine present 15.96 10.90 8 50078 924 110538289
Product use in unapproved indication 15.88 10.90 128 49958 447249 110091964
Nocturia 15.87 10.90 28 50058 16962 110522251
Neutrophil percentage increased 15.85 10.90 15 50071 4898 110534315
Food refusal 15.81 10.90 8 50078 942 110538271
Unresponsive to stimuli 15.81 10.90 64 50022 63726 110475487
Urine odour abnormal 15.58 10.90 18 50068 7397 110531816
Blood urine present 15.41 10.90 34 50052 24211 110515002
Drug-induced liver injury 15.41 10.90 19 50067 120048 110419165
Burning sensation 15.25 10.90 67 50019 69145 110470068
Stress urinary incontinence 15.23 10.90 10 50076 1923 110537290
Death 14.87 10.90 418 49668 698451 109840762
Nail disorder 14.72 10.90 4 50082 57931 110481282
Haematocrit decreased 14.57 10.90 64 50022 66053 110473160
Injection related reaction 14.51 10.90 9 50077 1569 110537644
Musculoskeletal pain 14.51 10.90 39 50047 182984 110356229
Repetitive strain injury 14.42 10.90 5 50081 227 110538986
Liver injury 14.37 10.90 29 50057 150384 110388829
Hydronephrosis 14.31 10.90 30 50056 20635 110518578
Oedema 14.30 10.90 48 50038 209928 110329285
Cerebral atrophy 14.19 10.90 19 50067 9066 110530147
Blood cholesterol increased 14.18 10.90 40 50046 184745 110354468
Perthes disease 14.13 10.90 3 50083 19 110539194
Upper limb fracture 14.09 10.90 30 50056 20858 110518355
Pregnancy 14.01 10.90 3 50083 51064 110488149
Autonomic dysreflexia 13.90 10.90 6 50080 493 110538720
Impaired gastric emptying 13.87 10.90 23 50063 13252 110525961
Urticaria 13.87 10.90 86 50000 318771 110220442
Lethargy 13.86 10.90 81 50005 93495 110445718
Thyroglobulin increased 13.81 10.90 4 50082 100 110539113
Resting tremor 13.79 10.90 9 50077 1714 110537499
Cerebrovascular accident 13.77 10.90 134 49952 181150 110358063
Tremor 13.70 10.90 146 49940 202086 110337127
Asthenia 13.53 10.90 408 49678 688591 109850622
Cytomegalovirus infection 13.39 10.90 4 50082 54440 110484773
Rash 13.36 10.90 277 49809 820687 109718526
Pulmonary fibrosis 13.25 10.90 16 50070 102026 110437187
Neuralgia 13.11 10.90 50 50036 48428 110490785
Anal incontinence 13.07 10.90 30 50056 21934 110517279
Depression 13.03 10.90 209 49877 317126 110222087
Vulvovaginal mycotic infection 12.92 10.90 14 50072 5363 110533850
Bone marrow failure 12.92 10.90 5 50081 57843 110481370
Renal impairment 12.89 10.90 43 50043 188402 110350811
Ankle fracture 12.83 10.90 28 50058 19791 110519422
Autoimmune disorder 12.56 10.90 7 50079 65476 110473737
Sciatica 12.53 10.90 14 50072 92385 110446828
Central nervous system lesion 12.47 10.90 24 50062 15529 110523684
Sleep disorder 12.47 10.90 47 50039 198597 110340616
Incision site pruritus 12.27 10.90 3 50083 38 110539175
Hypertonia 12.25 10.90 17 50069 8389 110530824
Salivary gland disorder 12.23 10.90 5 50081 359 110538854
Lumbar puncture abnormal 12.20 10.90 3 50083 39 110539174
Nasopharyngitis 12.15 10.90 117 49969 394244 110144969
Bladder operation 12.08 10.90 7 50079 1080 110538133
Agitation 11.98 10.90 90 49996 112961 110426252
Granulocytopenia 11.93 10.90 21 50065 12694 110526519
Musculoskeletal stiffness 11.90 10.90 76 50010 279746 110259467
Hip fracture 11.87 10.90 39 50047 35112 110504101
Hepatotoxicity 11.84 10.90 7 50079 63393 110475820
On and off phenomenon 11.48 10.90 12 50074 4412 110534801
Citric acid urine increased 11.45 10.90 3 50083 51 110539162
Sinusitis 11.41 10.90 83 50003 296605 110242608
Shock 11.38 10.90 5 50081 53583 110485630
Urinary tract infection enterococcal 11.37 10.90 11 50075 3691 110535522
Pyelonephritis 11.35 10.90 31 50055 25219 110513994
Neutrophil count increased 11.30 10.90 38 50048 34614 110504599
Urinary straining 11.29 10.90 3 50083 54 110539159
Encephalopathy 11.26 10.90 69 50017 80986 110458227
Wrist fracture 11.26 10.90 22 50064 14395 110524818
Adjustment disorder with depressed mood 11.21 10.90 3 50083 43880 110495333
Haematuria 11.12 10.90 70 50016 82935 110456278
Pneumonia influenzal 11.11 10.90 11 50075 3794 110535419
Familial haemophagocytic lymphohistiocytosis 11.09 10.90 3 50083 58 110539155
Visual impairment 11.02 10.90 101 49985 134327 110404886
Prescription drug used without a prescription 10.98 10.90 13 50073 5483 110533730
Abdominal pain 10.94 10.90 307 49779 512682 110026531
Occupational exposure to product 10.94 10.90 6 50080 833 110538380
Back pain 10.92 10.90 232 49854 370764 110168449

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC G04BD04 GENITO URINARY SYSTEM AND SEX HORMONES
UROLOGICALS
UROLOGICALS
Drugs for urinary frequency and incontinence
FDA MoA N0000000125 Cholinergic Muscarinic Antagonists
MeSH PA D010276 Parasympatholytics
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018678 Cholinergic Agents
MeSH PA D018680 Cholinergic Antagonists
MeSH PA D018727 Muscarinic Antagonists
MeSH PA D064804 Urological Agents
FDA EPC N0000175700 Cholinergic Muscarinic Antagonist
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:35846 renal agent
CHEBI has role CHEBI:36333 local anaesthetic
CHEBI has role CHEBI:38215 calcium channel blocker
CHEBI has role CHEBI:48876 muscarinic antagonist
CHEBI has role CHEBI:50370 parasympatholytic
CHEBI has role CHEBI:51371 muscle relaxant
CHEBI has role CHEBI:53784 antispasmodic drug

Related Drugs by ATC class:

G04BD Drugs for urinary frequency and incontinence 13 drugs
darifenacinemeproniumfesoterodineflavoxateimidafenacinmeladrazinemirabegronpropiverinesolifenacinterodilinetolterodinetrospium show all 13 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Urgent desire to urinate indication 75088002
Urge incontinence of urine indication 87557004
Bladder muscle dysfunction - overactive indication 236633002
Hyperhidrosis of palms indication 303090009
Neurogenic bladder indication 398064005
Increased Urinary Frequency indication
Sinus tachycardia contraindication 11092001
Severe chronic ulcerative colitis contraindication 14311001
Toxic megacolon contraindication 28536002 DOID:1770
Atony of colon contraindication 29479008
Hyperthyroidism contraindication 34486009 DOID:7998
Hypertensive disorder contraindication 38341003 DOID:10763
Conduction disorder of the heart contraindication 44808001
Chronic heart failure contraindication 48447003
Paralytic ileus contraindication 55525008 DOID:8442
Ulcerative colitis contraindication 64766004 DOID:8577
Hiatal hernia contraindication 84089009 DOID:12642
Kidney disease contraindication 90708001 DOID:557
Myasthenia gravis contraindication 91637004 DOID:437
Gastrointestinal obstruction contraindication 126765001
Gastroesophageal reflux disease contraindication 235595009 DOID:8534
Disease of liver contraindication 235856003 DOID:409
Bladder outflow obstruction contraindication 236645006
Benign prostatic hyperplasia contraindication 266569009
Retention of urine contraindication 267064002
Drowsy contraindication 271782001
Gastric retention contraindication 307227006
Angle-closure glaucoma contraindication 392291006 DOID:13550
Disorder of coronary artery contraindication 414024009
Gastrointestinal hypomotility contraindication 421807004




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.67 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
10% (100MG/PACKET) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** GELNIQUE ABBVIE N022204 Jan. 27, 2009 DISCN GEL TRANSDERMAL 10449173 Nov. 6, 2029 TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE WITH A SINGLE UNIT DOSE OF 10% OXYBUTYNIN CHLORIDE GEL
10% (100MG/PACKET) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** GELNIQUE ABBVIE N022204 Jan. 27, 2009 DISCN GEL TRANSDERMAL 9259388 Nov. 6, 2029 TREATMENT OF OVERACTIVE BLADDER BY APPLICATION OF OXYBUTYNIN CHLORIDE GEL TO SKIN
10% (100MG/PACKET) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** GELNIQUE ABBVIE N022204 Jan. 27, 2009 DISCN GEL TRANSDERMAL 8920392 March 26, 2031 TREATMENT OF OVERACTIVE BLADDER BY APPLICATION OF OXYBUTYNIN CHLORIDE GEL TO SKIN

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Muscarinic acetylcholine receptor M1 GPCR ANTAGONIST Ki 9 CHEMBL DRUG LABEL
Muscarinic acetylcholine receptor M3 GPCR ANTAGONIST Ki 9.11 CHEMBL DRUG LABEL
5-hydroxytryptamine receptor 2B GPCR Ki 6.30 DRUG MATRIX
D(3) dopamine receptor GPCR Ki 6.84 DRUG MATRIX
Muscarinic acetylcholine receptor M2 GPCR ANTAGONIST Ki 8.09 CHEMBL
Muscarinic acetylcholine receptor M4 GPCR Ki 8.44 CHEMBL
Muscarinic acetylcholine receptor M5 GPCR Ki 7.85 CHEMBL
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 7.99 DRUG MATRIX
Cytochrome P450 2C19 Enzyme IC50 6.22 DRUG MATRIX
Sodium-dependent dopamine transporter Transporter Ki 7.17 DRUG MATRIX
Sodium-dependent noradrenaline transporter Transporter Ki 5.59 DRUG MATRIX
Membrane-associated progesterone receptor component 1 Membrane receptor Ki 6.09 DRUG MATRIX
Muscarinic acetylcholine receptor M2 GPCR Ki 8.16 CHEMBL
Muscarinic acetylcholine receptor M1 GPCR Ki 8.23 CHEMBL
Muscarinic acetylcholine receptor M3 GPCR Ki 9.02 CHEMBL

External reference:

IDSource
4018815 VUID
N0000147118 NUI
D00465 KEGG_DRUG
1508-65-2 SECONDARY_CAS_RN
4018815 VANDF
4019869 VANDF
C0069805 UMLSCUI
CHEBI:7856 CHEBI
CHEMBL1231 ChEMBL_ID
CHEMBL1133 ChEMBL_ID
DB01062 DRUGBANK_ID
C005419 MESH_SUPPLEMENTAL_RECORD_UI
4634 PUBCHEM_CID
359 IUPHAR_LIGAND_ID
1354 INN_ID
K9P6MC7092 UNII
151651 RXNORM
180 MMSL
28244 MMSL
4610 MMSL
46359 MMSL
5214 MMSL
d00328 MMSL
001768 NDDF
004715 NDDF
31815007 SNOMEDCT_US
35768004 SNOMEDCT_US
372717000 SNOMEDCT_US
K9P6MC7092 INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
OXYTROL HUMAN PRESCRIPTION DRUG LABEL 1 0023-6153 PATCH 3.90 mg TRANSDERMAL NDA 29 sections
Oxytrol for Women HUMAN OTC DRUG LABEL 1 0023-9637 PATCH 3.90 mg TRANSDERMAL NDA 16 sections
oxybutynin HUMAN PRESCRIPTION DRUG LABEL 1 0615-8219 TABLET, FILM COATED, EXTENDED RELEASE 5 mg ORAL ANDA 23 sections
oxybutynin HUMAN PRESCRIPTION DRUG LABEL 1 0615-8220 TABLET, FILM COATED, EXTENDED RELEASE 10 mg ORAL ANDA 23 sections
OXYBUTYNIN CHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0615-8492 TABLET 5 mg ORAL ANDA 20 sections
Oxybutynin Chloride HUMAN PRESCRIPTION DRUG LABEL 1 0832-0038 TABLET 5 mg ORAL ANDA 23 sections
Oxybutynin Chloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-6570 TABLET, EXTENDED RELEASE 5 mg ORAL ANDA 25 sections
Oxybutynin Chloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-7027 TABLET 5 mg ORAL ANDA 20 sections
Oxybutynin Chloride HUMAN PRESCRIPTION DRUG LABEL 1 10135-609 TABLET, EXTENDED RELEASE 5 mg ORAL ANDA 29 sections
Oxybutynin Chloride HUMAN PRESCRIPTION DRUG LABEL 1 10135-610 TABLET, EXTENDED RELEASE 10 mg ORAL ANDA 29 sections
Oxybutynin Chloride HUMAN PRESCRIPTION DRUG LABEL 1 10135-611 TABLET, EXTENDED RELEASE 15 mg ORAL ANDA 29 sections
Oxybutynin Chloride HUMAN PRESCRIPTION DRUG LABEL 1 10135-640 TABLET 5 mg ORAL ANDA 23 sections
Oxybutynin Chloride HUMAN PRESCRIPTION DRUG LABEL 1 10544-518 TABLET 5 mg ORAL ANDA 24 sections
Oxybutynin Chloride HUMAN PRESCRIPTION DRUG LABEL 1 10544-559 TABLET 5 mg ORAL ANDA 21 sections
Oxybutynin Chloride HUMAN PRESCRIPTION DRUG LABEL 1 10702-201 TABLET 5 mg ORAL ANDA 22 sections
oxybutynin chloride HUMAN PRESCRIPTION DRUG LABEL 1 16729-317 TABLET, EXTENDED RELEASE 5 mg ORAL ANDA 26 sections
oxybutynin chloride HUMAN PRESCRIPTION DRUG LABEL 1 16729-318 TABLET, EXTENDED RELEASE 10 mg ORAL ANDA 26 sections
oxybutynin chloride HUMAN PRESCRIPTION DRUG LABEL 1 16729-319 TABLET, EXTENDED RELEASE 15 mg ORAL ANDA 26 sections
Oxybutynin Chloride HUMAN PRESCRIPTION DRUG LABEL 1 17856-0092 SYRUP 5 mg ORAL ANDA 17 sections
Oxybutynin Chloride HUMAN PRESCRIPTION DRUG LABEL 1 17856-0149 SYRUP 5 mg ORAL ANDA 21 sections
Oxybutynin Chloride HUMAN PRESCRIPTION DRUG LABEL 1 17856-1491 SOLUTION 5 mg ORAL ANDA 23 sections
Oxybutynin Chloride HUMAN PRESCRIPTION DRUG LABEL 1 21695-406 TABLET 5 mg ORAL ANDA 23 sections
Oxybutynin Chloride HUMAN PRESCRIPTION DRUG LABEL 1 23155-810 TABLET 5 mg ORAL ANDA 21 sections
Oxybutynin Chloride HUMAN PRESCRIPTION DRUG LABEL 1 23155-913 TABLET 5 mg ORAL ANDA 13 sections
Oxybutynin Chloride Human Prescription Drug Label 1 27241-155 TABLET, EXTENDED RELEASE 5 mg ORAL ANDA 25 sections
Oxybutynin Chloride Human Prescription Drug Label 1 27241-156 TABLET, EXTENDED RELEASE 10 mg ORAL ANDA 25 sections
Oxybutynin Chloride Human Prescription Drug Label 1 27241-157 TABLET, EXTENDED RELEASE 15 mg ORAL ANDA 25 sections
Oxybutynin Chloride HUMAN PRESCRIPTION DRUG LABEL 1 33261-342 TABLET 5 mg ORAL ANDA 24 sections
Oxybutynin Chloride HUMAN PRESCRIPTION DRUG LABEL 1 42291-456 TABLET 5 mg ORAL ANDA 21 sections
Oxybutynin ChlorideExtended Release HUMAN PRESCRIPTION DRUG LABEL 1 42291-633 TABLET, EXTENDED RELEASE 5 mg ORAL ANDA 26 sections